ClinicalTrials.gg
CompletedNCT03704519Updated Oct 30, 2020

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

A Phase 1 interventional study of Darolutamide (BAY1841788) and Enzalutamide in Cerebrovascular Circulation, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-30.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The current study would investigate the effects of a single dose of darolutamide and enzalutamide compared with placebo and compared to each other on human brain blood flow using arterial spin labeling magnetic resonance imaging (ASL-MRI), a non-invasive MRI technique. The change in cerebral blood flow was an indirect measure of brain penetration.

The risk of drug-associated CNS-related adverse events was likely to be correlated with the concentration of the drug in the brain. In contrast to enzalutamide, preclinical studies of darolutamide indicate that its brain penetration was much lower.

The aim of this study was to determine whether there was a difference between darolutamide and enzalutamide compared to placebo in cerebral blood flow and thus in brain penetration.

Read the detailed description

The primary objective was to investigate drug-induced changes in grey matter cerebral blood flow during single-dose treatment with darolutamide or enzalutamide as compared to placebo using voxel-wise quantification of the grey matter for the entire brain.

The secondary objective was to investigate drug-induced changes in regional cerebral blood flow in brain areas related to cognitive function after single-dose treatment.

02

Conditions studied

  • Cerebrovascular Circulation

Keywords

  • Healthy volunteers
  • Magnetic Resonance Imaging (MRI)
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy as determined by medical history, physical examination, laboratory tests, and cardiac monitoring.

Exclusion criteria

Exclusion Criteria:

  • Existing or recent relevant diseases of vital organs (eg, liver diseases, heart diseases, renal disease, lung disease), central nervous system or other organs (eg, Diabetes mellitus, myasthenia gravis).
  • Known to magnetic resonance imaging.
  • Any structural variants or pathological abnormalities on structural brain MRI during screening.
  • Any history of seizures including a febrile seizure in childhood, loss of consciousness, , or any condition that may pre-dispose to seizure.
  • Participant with any type of neurological problems or history of psychiatric disorder, especially mood disorders including medical history with suicidal ideation and/or suicide attempts, which may disable the participant to consent to the study.
  • Participants who use prescription or oral over the counter medications which might influence the study objectives, dietary/nutritional supplements, (including vitamins, natural and herbal remedies, eg, St. John's wort) within 2 weeks prior to first study intervention administration or during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Men_EPD

    Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

  • Experimental
    Men_DEP

    Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

  • Experimental
    Men_PDE

    Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

  • Experimental
    Men_DPE

    Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

  • Experimental
    Men_EDP

    Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

  • Experimental
    Men_PED

    Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.

    Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo

Interventions

  • 300 mg tablet darolutamide, once orally

    Also known as: Darolutamide: ODM-201

  • 4 x 40 mg capsules, once orally

    Also known as: MDV3100

  • OtherPlacebo

    4 placebo tablets, once orally

    Also known as: Darolutamide-matching placebo

06

What researchers measure

Primary outcomes

  1. Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo

    Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to placebo. Measured in grey matter voxels with arterial spin labeling magnetic resonance imaging (ASL-MRI).

    Time frame: At 4 hours after drug

  2. Change in grey-matter cerebral blood flow of darolutamide as compared to placebo

    Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of darolutamide to placebo. Measured in grey matter voxels with ASL-MRI.

    Time frame: At 4 hours after drug

  3. Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide

    Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to darolutamide. Measured in grey matter voxels with ASL-MRI.

    Time frame: At 4 hours after drug

Secondary outcomes

  1. Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to placebo

    Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.

    Time frame: At 4 hours after drug

  2. Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of darolutamide as compared to placebo

    Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.

    Time frame: At 4 hours after drug

  3. Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to darolutamide

    Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.

    Time frame: At 4 hours after drug

07

Study locations

1 site
  • Centre for Neuroimaging Sciences, King's College
    London, SE5 8AF, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Oct 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Oct 12, 2018
StartActual
Oct 23, 2018
Primary completionActual
Oct 1, 2019
CompletionActual
Nov 5, 2019
Last update
Oct 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03704519
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 12, 2018
Start date
Oct 23, 2018
Primary completion
Oct 1, 2019
Completion
Nov 5, 2019
Last update
Oct 30, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Enzalutamide

Start the discussion